| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A recombinant human UCHL1 protein was used as the immunogen for the PGP9.5 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
PGP9.5 Antibody / UchL1 is an antibody targeting PGP9.5. Host: Mouse. Monoclonal. Clone: UCHL1/8153. Format: Purified. Applications: IHC-P, WB.
Key elements and design rationale
- Target: PGP9.5.
- Immunogen: A recombinant human UCHL1 protein was used as the immunogen for the PGP9.5 antibody..
- Species reactivity: Human.
- Localization: Cytoplasm, Endoplasmic reticulum membrane.
- Conjugate: Unconjugated (no label listed).
Biological background (from provided description)
This MAb reacts with a protein of 20-30kDa, identified as PGP9.5, also known as ubiquitin carboxyl-terminal hydrolase-1 (UchL1).
Common research applications
- WB: relative abundance and band pattern assessment using appropriate controls.
- IHC: tissue distribution assessment; interpret with matched controls.
Notes for experimental interpretation
- Account for isoforms, paralogs, and post-translational modifications when interpreting signal.
- Support specificity with biological controls (e.g., KO/KD where available) and technical controls (e.g., secondary-only/isotype).
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
